What future for ribavirin?

Liver International

Volumn 29, Issue SUPPL. 1, 2009, Pages 68-73

  Shiffman, Mitchell L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chronic HCV; HCV treatment; Ribavirin

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; RIBAVIRIN; RIBAVIRIN DERIVATIVE; TELAPREVIR; TERABAVIRIN; UNCLASSIFIED DRUG;

ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; IMMUNE RESPONSE; MONOTHERAPY; NAUSEA; TERATOGENICITY; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; PROTEASE INHIBITORS; RIBAVIRIN; VIRAL NONSTRUCTURAL PROTEINS;

EID: 59149106172     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01936.x     Document Type: Conference Paper

References (39)

1. Fernandez H, Banks G, Smith R. Ribavirin: A clinical overview. Eur J Epidemiol 1986; 2: 1-14.
2. Murata Y, Falsey AR. Respiratory syncytial virus infection in adults. Antiviral Ther 2007; 12: 659-70.
3. Glanville AR, Scott AI, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2005; 24: 2114-9.
4. Snell NJ. Ribavirin-current status of a broad spectrum antiviral agent. Expert Opin Pharmacother 2001; 2: 1317-24.
5. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
6. Fried MW, Shiffman ML, Reddy KR, et al. Combination of peginterferon alfa-2a (40kd) plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
7. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358: 958-65.
8. Patterson JL, Fernandez-Larson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990; 12: 1139-46.
9. Cameron CE, Castro C. The mechanism of action of ribavirin: Lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr Opin Infect Dis 2001; 14: 757-64.
10. Potter CW, Phair JP, Vodinelich L, Fenton R, Jennings R. Antiviral, immunosuppressive and antitumour effects of ribavirin. Nature 1976; 259: 496-7.
11. Bodenheimer Jr HC, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997; 26: 473-7.
12. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37: 1351-8.
13. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005; 43: 453-71.
14. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131: 1040-8.
15. Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Int Med 2004; 140: 346-55.
16. Jacobson IM, Brown Jr RS, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial. Hepatology 2007; 46: 971-81.
17. Shiffman ML. Side effects of medical therapy for chronic hepatitis C. Ann Hepatol 2004; 3: 5-10.
18. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19(Suppl. 1): 17-24.
19. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.
20. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19(Suppl. 1): 67-75.
21. McHutchison JG, Manns MP, Brown Jr RS, et al. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007; 102: 880-9.
22. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
23. Shiffman ML. Optimizing the current therapy for chronic hepatitis C virus: Peginterferon and ribavirin dosing and the utility of growth factors. Clin Liver Dis 2008; 12: 487-505.
24. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103-12.
25. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2006; 5: 124-9.
26. Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004; 40: 1450-8.
27. Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006; 44: 1598-606.
28. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46: 371-9.
29. Alvarez D, Dieterich DT, Brau N, et al. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006; 13: 683-9.
30. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.
31. Wu JZ, Yeh LT, Lin CC, Hong Z. Conversion of viramidine to ribavirin in vivo by adenosine deaminase and its inhibition by 2′-deoxycoformycin. Antiviral Chem Chemother 2006; 17: 33-9.
32. Gish R, Nelson D, Arora S, et al. Virologic response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with viramadine in combination with pegylated interferon alfa-2a. J Hepatol 2005; 42(Suppl. 2): 39.
33. Benhamou Y, Pockros P, Rodriquez-Torres M, et al. The safety and efficacy of viramadine plus pegylated interferon alfa-2b versus ribavirin plus pegylated interferon alfa-2b in therapy naive patients infected with chronic HCV. Phase 3 results. J Hepatol 2006; 44(Suppl. 2): S273.
34. Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008; 48: 385-97.
35. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008; 49: 163-9.
36. Mchutchison JG, Everson GT, Gordon SC, et al. Prove 1: Results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naïve subjects with hepatitis C. J Hepatol 2008; 48(Suppl. 2): S4.
37. Dusheiko GM, Hezode C, Pol S, et al. Treatment of chronic hepatitis C with telaprevir in combination with peginterferon alfa-2a with or without ribavirin: Further interim analysis results of the prove 2 study. J Hepatol 2008; 48(Suppl. 2): S26.
38. Kwo P, Lawitz E, McCone J, et al. Interm results from HCV sprint-1: RVR/ EVR from phase 2 study of boceprevir plus pegintron (peginterferon alfa-2b)/ribavirin in treatment naïve subjects with genotype-1 CHC. J Hepatol 2008; 48(Suppl. 2): S372.
39. McHutchison JG, Shiffman ML, Terrault N, et al. A phase 2b study of telaprevir with peginterferon alfa-2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon alfa-2a/b and ribavirin therapy. Prove 3 interim results. Hepatology 2008; 48(suppl): 431A.